Scinai Immunotherapeutics Ltd. (SCNI) Stock Overview
Explore Scinai Immunotherapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Scinai Immunotherapeutics Ltd. (SCNI)
Key Financials
Key Financials
Market Cap
589.3K
P/E Ratio
-0.00
EPS (TTM)
$-14.23
ROE
-0.27%
SCNI Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Scinai Immunotherapeutics Ltd.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of SCNI on the NASDAQ shows an RSI of 40.42, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $2.64 for the NASDAQ listing.
Key metrics behind Scinai Immunotherapeutics Ltd.'s NASDAQ-traded stock include a P/E ratio of -0.00 and a market capitalization of 589.3K. Combined with our AI analysis, these give both institutional and retail investors a clear view of SCNI on the NASDAQ.